Pharmaceutical

How CNS researchers are handling clinical trial turbulence

The field of central nervous system (CNS) drug development is awash with activit...

NICE green lights two blood cancer therapies for NHS use

BMS' Breyanzi and Amgen’s Blincyto will now be available to patients in England ...

Incyte and Genesis collaborate on small-molecule medicines

Incyte and Genesis have entered a strategic partnership for the research, discov...

Struggling bluebird bio to go private for less than $30m

Bluebird has faced financial pressures over the last few years, leading to sever...

Pfizer shelves haemophilia gene therapy Beqvez amid low...

Pfizer said resources will be directed to its other haemophilia gene therapy Hym...

UroGen acquires IconOVir’s oncolytic virus assets

UroGen Pharma has broadened its oncology pipeline by acquiring IconOVir Bio’s as...

GLP-1 receptor agonists could hold promise for opioid u...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for t...

FibroGen sells China unit to AstraZeneca for $160m

AstraZeneca will gain full rights for roxadustat in China where it is approved t...

Zealand Pharma steadfastly upholds amylin-based obesity...

Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants t...

X4 and taiba to distribute WHIM syndrome therapy in Mid...

X4 has entered an exclusive agreement with taiba rare for distributing and comme...

Key pharma launch trends in 2024

In this review, GlobalData considers the products both approved and priced in 20...

WHO targets over half a million children in Gaza for po...

The World Health Organization (WHO) said it will conduct another mass vaccinatio...

FDA authorises ImmunityBio’s BCG alternative to treat b...

ImmunityBio has gained the FDA authorisation for an EAP to supply an alternative...

Pharma and medtech industry reacts to FDA, CDC and NIH ...

The FDA, NIH and CDC has cut 5,200 probationary staff in a job cull across the H...

FDA grants priority review for Boehringer’s zongertinib...

FDA has granted priority review for Boehringer Ingelheim’s zongertinib NDA for t...